Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

Provides are approaches for anticancer and antiaging treatments by administration of reverse transcriptase (RT) activity inhibitors that function to inhibit RT encoded by ORF2 of LINE1, or any RT that can participate in transcriptional activation of retroelements. Also provided are approaches to discovery of new compounds that can inhibit RTs, and identifying individuals who would benefit from treatment with such RT inhibitors, and treating such individuals. The methods are applicable for use in populations of cancer cells, pre-cancerous cells, somatic cells, and combinations thereof. Also provided are methods for monitoring the efficacy of a treatment that inhibits development of resistance to pharmaceutical agents, methods for prophylaxis and/or therapy for a pathology correlated with accumulation of somatic cells capable of spontaneously generating genetic alterations independently of cell divisions, wherein such cells express functional LINE1 elements. Also provides are methods for treating and/or preventing age-related conditions in an individual by administering an agent capable of selectively killing the cells that exhibit genetic instability as evidenced by expression of functional LINE 1. Also provided are methods for sensitizing cancer cells to a chemotherapeutic agent by administering an RT inhibitor.

In one aspect, the invention features a method for identifying a drug-modulated polypeptide substrate of cereblon (CRBN). In another aspect, the invention features a method of identifying a polypeptide target of a modulator of CRBN. In yet another aspect, the invention provides methods of monitoring or characterizing the sensitivity of a subject to a modulator of CRBN.

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

The invention relates to purified, tissue-specific progenitors, methods of making and using such tissue-specific progenitors.

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

Disclosed herein are methods of detecting a target nucleic acid sequence, determining the localization of the target nucleic acid sequence, and/or quantifying the number of target nucleic acid sequences in a cell. This method may be used on small target nucleic acid sequences, and may be referred to as Nano-FISH.

The present invention provides a non-naturally occurring dendritic-like myeloid leukaemia cell according to ATCC Patent Deposit Designation PTA-123875, and methods and kits utilising such cells.

Providing a human primary myelofibrosis (PMF) cell strain, a construction method therefor and use thereof. The PMF cell strain is named as ZYXY-M2, and is deposited in China Center for Type Culture Collection (Wuhan University, Wuhan, China), with a preservation number of CCTCC NO: C202145. The present application is obtained by extracting and separating mononuclear cells from peripheral blood of a PMF patient and culturing in vitro for continuous natural passage. The leukemia cell strain is negative for JAK2, CALR, MPL mutation, positive for ASXL1, TP53, IKZF1, IDH1, FLT3 and TET1. The cell strain has good proliferation ability in vitro, and can be used as a cell material to study the pathogenesis of PMF and individualized treatment in vitro. Meanwhile, it can also be used to screen and evaluate drugs for in vitro and in vivo research of human PMF and guide clinical medication.

The present invention relates to a method for obtaining a population of oncogenic cells modified comprising the following steps: i) obtaining a population of oncogenic cells from a subject suffering from a cancer; and ii) treating said cells with a fusion protein comprising an AAC-11 leucine-zipper (LZ) derived peptide which is fused to at least one heterologous polypeptide. Inventors have evaluated here the antileukemic efficacy of RT53, an anticancer peptide with potential immunological properties. Their results indicate that RT53 possesses a direct antileukemic effect, even at late stage. They also demonstrated that single injection of a vaccine consisting of leukemic blasts exposed to RT53, which induces the hallmarks of immunogenic cell death, was highly effective in preventing leukemia development in both prophylactic and therapeutic settings. The vaccine comprising RT53-treated APL cells generated long-term antileukemic protection and depletion experiments indicated that CD4+ T cells were of crucial importance for vaccine efficacy. Combined, their results provide the rational for the exploration of RT53-based therapies for the treatment of cancer, such as acute leukemia.